Source-grounded facts extracted from INCYTE CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INCYTE CORP reported first quarter of 2026 results: revenue $1.27 billion.
“furnished as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi ® (ruxolitinib) net sales”
Barry P. Flannelly retired as Executive Vice President, General Manager, North America at INCYTE CORP.
“On January 6, 2025, Barry P. Flannelly, Executive Vice President, General Manager, North America of Incyte Corporation (the “Company”), announced his retirement from the Company and stepped down from that role on that date, effective with the commencement of employment of his successor.”
INCYTE CORP entered into Purchase Agreement with Baker Entities (including Julian C. Baker, Felix J. Baker, and affiliates) valued at approximately $328.0 million (effective 2024-05-12).
“On May 12, 2024, Incyte Corporation (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with Julian C. Baker, a member of the Company’s board of directors, Felix J. Baker, and entities affiliated with Julian C. and Felix J. Baker, including funds advised by Baker Bros. Advisors LP (collectively, the “Baker Entities”).”
INCYTE CORP reported first fiscal quarter ended March 31, 2024 results: revenue Total revenues of $881 million in the first quarter (Q1'24). Guidance reaffirmed.
“Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $881 million in the first quarter (Q1'24) (+9% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $572 million in Q1'24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of $2,690 - $2,750 million”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.